Coldstream Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $474K | Buy |
3,775
+125
| +3% | +$15.7K | 0.01% | 682 |
|
|
2025
Q1 | $404K | Sell |
3,650
-429
| -11% | -$47.4K | 0.01% | 704 |
|
|
2024
Q4 | $557K | Buy |
4,079
+162
| +4% | +$22.1K | 0.01% | 560 |
|
|
2024
Q3 | $452K | Buy |
3,917
+516
| +15% | +$59.6K | 0.01% | 643 |
|
|
2024
Q2 | $468K | Buy |
3,401
+47
| +1% | +$6.47K | 0.01% | 576 |
|
|
2024
Q1 | $463K | Buy |
3,354
+146
| +5% | +$20.1K | 0.01% | 585 |
|
|
2023
Q4 | $423K | Buy |
3,208
+868
| +37% | +$114K | 0.01% | 573 |
|
|
2023
Q3 | $263K | Buy |
+2,340
| New | +$263K | 0.01% | 643 |
|
|
2023
Q2 | – | Sell |
-2,796
| Closed | -$283K | – | 854 |
|
|
2023
Q1 | $283K | Sell |
2,796
-577
| -17% | -$58.4K | 0.01% | 643 |
|
|
2022
Q4 | $403K | Buy |
+3,373
| New | +$403K | 0.01% | 495 |
|
|
2022
Q2 | $305K | Buy |
3,123
+891
| +40% | +$87K | 0.01% | 558 |
|
|
2022
Q1 | $209K | Buy |
+2,232
| New | +$209K | 0.01% | 736 |
|